Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
Breast Cancer: Targets and Therapy · 2026-04 · Volume 18 · 1-13
DOI: 10.2147/bctt.s598598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-04. Verfasst von Zeliha Birsin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
ORCID-Profile: Zeliha Birsin, Murad Guliyev, Emir Çerme, Hamza Abbasov, Murat Sarı, Özkan Alan
Zitieren
APA
Birsin, Z., Güren, A. K., Aliyev, V., Guliyev, M., Jeral, S., Cebeci, S., Çerme, E., Günaltılı, M., Abbasov, H., Çiçek, E., Atak, S., Sarı, M., Demirci, N. S., & Alan, Ö. (2026). Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study. Breast Cancer: Targets and Therapy, Volume 18, 1-13. https://doi.org/10.2147/bctt.s598598
Vancouver
Birsin Z, Güren AK, Aliyev V, Guliyev M, Jeral S, Cebeci S, et al. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-13. doi:10.2147/bctt.s598598
BibTeX
@article{Birsin2026,
author = {Birsin, Zeliha and Güren, Ali Kaan and Aliyev, Vali and Guliyev, Murad and Jeral, Seda and Cebeci, Selin and Çerme, Emir and Günaltılı, Murat and Abbasov, Hamza and Çiçek, Ebru and Atak, Süheyla and Sarı, Murat and Demirci, Nebi Serkan and Alan, Özkan},
title = {Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study},
journal = {Breast Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 18},
pages = {1--13},
doi = {10.2147/bctt.s598598}
}
EUVIMED